Natera, Inc. $NTRA Stock Position Reduced by Vestmark Advisory Solutions Inc.

Key Points

• Vestmark Advisory Solutions Inc. reduced its stake in Natera, Inc. by 30.6% during the first quarter, selling 10,746 shares and holding 24,336 shares valued at approximately $3.44 million at the end of the quarter.
• Other institutional investors have increased their stakes, with HighPoint Advisor Group LLC raising it by 30.8% and 99.90% of Natera's stock now being owned by institutional investors.
• Natera recently reported quarterly earnings of ($0.74) EPS, missing consensus estimates, but experienced a 32.2% increase in revenue compared to the same quarter last year, totaling $546.60 million.

Vestmark Advisory Solutions Inc. trimmed its holdings in Natera, Inc. (NASDAQ:NTRA - Free Report) by 30.6% in the first quarter, according to its most recent disclosure with the SEC. The fund owned 24,336 shares of the medical research company's stock after selling 10,746 shares during the period. Vestmark Advisory Solutions Inc.'s holdings in Natera were worth $3,441,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Fulton Bank N.A. raised its holdings in Natera by 2.0% during the first quarter. Fulton Bank N.A. now owns 3,652 shares of the medical research company's stock worth $516,000 after purchasing an additional 71 shares in the last quarter. QRG Capital Management Inc. grew its position in Natera by 1.5% during the first quarter. QRG Capital Management Inc. now owns 5,417 shares of the medical research company's stock worth $766,000 after buying an additional 81 shares during the period. Earned Wealth Advisors LLC grew its position in Natera by 5.0% during the first quarter. Earned Wealth Advisors LLC now owns 1,737 shares of the medical research company's stock worth $246,000 after buying an additional 82 shares during the period. Bridges Investment Management Inc. grew its position in Natera by 5.5% during the first quarter. Bridges Investment Management Inc. now owns 1,676 shares of the medical research company's stock worth $237,000 after buying an additional 87 shares during the period. Finally, Colonial Trust Co SC grew its position in Natera by 7.8% during the fourth quarter. Colonial Trust Co SC now owns 1,325 shares of the medical research company's stock worth $210,000 after buying an additional 96 shares during the period. 99.90% of the stock is owned by hedge funds and other institutional investors.

Natera Trading Up 2.0%

NTRA stock traded up $3.1430 during mid-day trading on Thursday, hitting $163.7830. 311,501 shares of the company were exchanged, compared to its average volume of 1,515,000. The company has a market capitalization of $22.48 billion, a PE ratio of -85.79 and a beta of 1.76. Natera, Inc. has a twelve month low of $110.57 and a twelve month high of $183.00. The firm has a fifty day simple moving average of $154.89 and a 200 day simple moving average of $154.48.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.14). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The company had revenue of $546.60 million for the quarter, compared to analyst estimates of $476.84 million. During the same period in the prior year, the business earned ($0.30) earnings per share. Natera's revenue was up 32.2% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Insider Transactions at Natera

In related news, CEO Steven Leonard Chapman sold 5,807 shares of Natera stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $132.88, for a total value of $771,634.16. Following the sale, the chief executive officer directly owned 163,593 shares in the company, valued at $21,738,237.84. This trade represents a 3.43% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Solomon Moshkevich sold 875 shares of the business's stock in a transaction dated Thursday, August 14th. The stock was sold at an average price of $155.46, for a total transaction of $136,027.50. Following the sale, the insider owned 123,859 shares in the company, valued at $19,255,120.14. This trade represents a 0.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 61,792 shares of company stock worth $9,227,972 over the last 90 days. Corporate insiders own 5.63% of the company's stock.

Analysts Set New Price Targets

NTRA has been the topic of several research reports. Wall Street Zen lowered shares of Natera from a "hold" rating to a "sell" rating in a research report on Saturday, May 17th. UBS Group increased their price target on shares of Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a research note on Friday, May 9th. Royal Bank Of Canada increased their price target on shares of Natera from $251.00 to $255.00 and gave the stock an "outperform" rating in a research note on Friday, August 8th. Evercore ISI raised shares of Natera to a "strong-buy" rating and set a $170.00 price target on the stock in a research note on Monday, July 28th. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $220.00 price target (up previously from $210.00) on shares of Natera in a research note on Monday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating and seventeen have issued a Buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $193.19.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.